TG Therapeutics Swings to Quarterly Profit, Targets Higher Revenue in 2025

Dow Jones
03 Mar
 

By Robb M. Stewart

 

TG Therapeutics Is targeting a further jump in revenue this year after swinging to a profit in the latest quarter with higher sales of its flagship treatment for relapsing forms of multiple sclerosis.

The commercial-stage biopharmaceutical company swung to a profit of $23.3 million, or 15 cents a share, from a year-earlier loss of $14.4 million, or 10 cents a share. Analysts polled by FactSet had penciled in per-share earnings of 16 cents for the quarter.

Revenue more than doubled to $108.2 million from $44 million in the same period last year.

Product revenue for the quarter totaled $107.3 million, primarily reflecting $103.6 million in sales of Briumvi, a monoclonal antibody used as a multiple sclerosis treatment.

A monoclonal antibody is a type of protein that can bind to certain targets in the body. Multiple sclerosis is a long-lasting disease of the central nervous system.

TG Therapeutics is targeting global revenue in 2025 of about $540 million, including Briumvi U.S. product revenue of roughly $525 million. Analysts were expected revenue this year of $534.4 million, after the company recorded 2024 revenue of $329 million.

Full-year operating expense is expected to be about $300 million, excluding non-cash compensation, the company said.

 

Write to Robb M. Stewart at robb.stewart@wsj.com

 

(END) Dow Jones Newswires

March 03, 2025 07:47 ET (12:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10